Abbott Reports Decent Third Quarter; Decides to Break Itself Into Two
Abbott (ABT) reported strong third-quarter results Wednesday and outlined plans to split itself into two distinct entities: one in diversified medical products and the other in research-based pharmaceuticals. We liked the quarter and are fans of management’s plans to break apart the company. Our $68 fair value estimate remains unchanged. Abbott’s worldwide sales advanced 13.2% from the prior-year period thanks to solid performance from proprietary pharmaceuticals and its durable growth business (nutritionals, established pharma, lab diagnostics, and diabetes care), and the firm was able to leverage such growth into 12.4% earnings-per-share expansion, excluding a $1.5 billion litigation reserve related to a previously-disclosed DOJ investigation (Depakote). Emerging market sales continue to be a key driver, jumping 21% from the prior-year period … Read more